Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Apatinib, and Eribulin in Advanced Triple-Negative Breast Cancer
NCT04303741Phase 2Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2020
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Overall Response Rate up to 24 months. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04303741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303741.